NOVARTIS
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset Seizures
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 93
- Registration Number
- NCT01147003
- Locations
- 🇺🇸
AMO Corporation, Tallahassee, Florida, United States
🇺🇸Thomas Jefferson University, Dept. of Psychiatry & Neurology, Philadelphia, Pennsylvania, United States
🇺🇸Medical Center of the Rockies, Loveland, Colorado, United States
Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 2417
- Registration Number
- NCT01127750
- Locations
- 🇩🇪
Neuroscience Research of the Berkshires, Krefeld, Germany
🇬🇧Novartis Investigational Site, Truro, United Kingdom
🇩🇪Novarris Investigative Site, Berlin, Germany
Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old)
- First Posted Date
- 2010-05-14
- Last Posted Date
- 2014-01-17
- Lead Sponsor
- Novartis
- Target Recruit Count
- 50
- Registration Number
- NCT01123941
- Locations
- 🇧🇪
Center for the Evaluation of Vaccination (CEV), Antwerp, Wilrijk (Antwerp), Belgium
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
- Conditions
- Interventions
- First Posted Date
- 2010-04-29
- Last Posted Date
- 2013-12-06
- Lead Sponsor
- Novartis
- Target Recruit Count
- 347
- Registration Number
- NCT01113047
- Locations
- 🇩🇪
Investigative Site, Pirna, Germany
Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis
- First Posted Date
- 2010-04-13
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Novartis
- Registration Number
- NCT01103024
- Locations
- 🇨🇭
Novartis Investigative Site, Bern, Switzerland
🇯🇵Novartis Investigational Site, Kyoto, Japan
🇺🇸Texas Retina Associates, Arlington, Texas, United States
Efficacy and Safety of AFQ056 When Combined With Increased Doses of L-dopa in Parkinson's Disease Patients With Moderate-severe L-dopa Induced Dyskinesia
- First Posted Date
- 2010-03-24
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 23
- Registration Number
- NCT01092065
- Locations
- 🇺🇸
The Parkinsons Institute, Sunnyvale, California, United States
🇺🇸Colorado Neurological Institute, Englewood, Colorado, United States
🇺🇸University of Kansas Medical Center - Parkinson's Disease and Movement Disorders Center, Kansas City, Kansas, United States
Efficacy and Tolerability of Carbamazepine CR in Diabetic Neuropathy Pain
- First Posted Date
- 2010-03-19
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 123
- Registration Number
- NCT01089855
- Locations
- 🇲🇦
Novartis Investigational Site, Rabat, Morocco
12-week Efficacy of Indacaterol
- Conditions
- Interventions
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2011-08-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 323
- Registration Number
- NCT01072448
- Locations
- 🇺🇸
Novartis Investigative site, Greer, South Carolina, United States
🇺🇸Novartis Investigator Site, Tacoma, Washington, United States
🇺🇸Novartis Investigative Site, Newport News, Virginia, United States
Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension
- Conditions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 230
- Registration Number
- NCT01070030
- Locations
- 🇹🇭
Investigative Site, Nakhon Ratchasima, Thailand
Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 115
- Registration Number
- NCT01069692
- Locations
- 🇮🇹
Novartis Investigator Site, Lucca, Italy
🇮🇹Novartis Investigative Site, Siena, Italy